Hims & Hers Health (HIMS) Revenue Growth (3y) (2023 - 2026)
Hims & Hers Health (HIMS) Revenue Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 2.94% |
| 10 | Hims & Hers Health | 6.77 Bn | 6.02 Bn | 396.79 Mn | 47.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.17% |
| Dec 31, 2025 | 54.60% |
| Sep 30, 2025 | 60.51% |
| Jun 30, 2025 | 68.66% |
| Mar 31, 2025 | 79.51% |
| Dec 31, 2024 | 78.43% |
| Sep 30, 2024 | 75.59% |
| Jun 30, 2024 | 73.26% |
| Mar 31, 2024 | 74.54% |
| Dec 31, 2023 | 81.18% |
| Sep 30, 2023 | 76.37% |
| Jun 30, 2023 | 79.57% |
| Mar 31, 2023 | 85.14% |